Previous data have shown that GALNT14 correlates with Apo2L/TRAIL sensitivity in pancreas cancer, non-small-cell lung cancer, and melanoma cell lines, with overexpression increasing response to treatment by leveraging O-glycosylation to mediate apoptosis-initiating protease caspase-8 [55], decreasing resistance to apoptosis. The gene discussed is TNFSF10; the disease is melanoma.